Table 3.
Significant loci identified by previous and current genome-wide association studies
| Locus | Chr. | Risk allele | OR (95% CI)a | P-valuea | Nearest gene | Reference |
|---|---|---|---|---|---|---|
| rs2212020 | 3p22.2 | T | 2.24 (1.59–3.15) | 8.27E−07 | ITGA9 | (13) |
| rs6774494 | 3q26.2 | A | 1.18 (1.11–1.25) | 5.05E−08 | MDS1-EVI1 | (15) |
| rs2267633 | 6p22.1 | A | 1.57 (1.36–1.82) | 1.28E−09 | GABBR1 | (14) |
| rs2076483 | 6p22.1 | A | 1.57 (1.36–1.82) | 1.49E−09 | GABBR1 | (14) |
| rs29230 | 6p22.1 | A | 1.56 (1.34–1.80) | 4.77E−09 | GABBR1 | (14) |
| rs29232 | 6p22.1 | A | 1.67 (1.48–1.88) | 8.97E−17 | GABBR1 | (14) |
| rs3129055 | 6p22.1 | G | 1.51 (1.34–1.71) | 7.36E−11 | HLA-F | (14) |
| rs9258122 | 6p22.1 | A | 1.49 (1.32–1.69) | 3.33E−10 | HLA-F | (14) |
| rs2860580 | 6p22.1 | G | 1.72 (1.61–1.85) | 3.65E−38 | HLA-A | (15) |
| rs2517713 | 6p22.1 | A | 1.88 (1.65–2.15) | 3.90E−20 | HLA-A | (14) |
| rs2975042 | 6p22.1 | A | 1.86 (1.63–2.13) | 1.60E−19 | HLA-A | (14) |
| rs9260734 | 6p22.1 | G | 1.85 (1.61–2.12) | 6.77E−18 | HCG9 | (14) |
| rs3869062 | 6p22.1 | A | 1.78 (1.55–2.05) | 8.68E−16 | HCG9 | (14) |
| rs5009448 | 6p22.1 | G | 1.72 (1.51–1.96) | 1.30E−15 | HCG9 | (14) |
| rs16896923 | 6p22.1 | A | 1.66 (1.42–1.94) | 2.49E−10 | HCG9 | (14) |
| MICA/HCP5 deletion | 6p21.33 | CN = 1 | 5.15 (1.96–13.58) | 2.27E−04 | MICA, HCP5 | Current study |
| rs2894207 | 6p21.33 | A | 1.64 (1.49–1.75) | 1.83E−31 | HLA-B/C | (15) |
| rs28421666 | 6p21.32 | A | 1.52 (1.39–1.67) | 1.40E−18 | HLA-DQ/DR | (15) |
| rs1412829 | 9p21.3 | A | 1.28 (1.16–1.41) | 3.51E−07 | CDNK2A/2B | (15) |
| rs9510787 | 13q12.12 | G | 1.14 (1.06–1.22) | 9.57E−09 | TNFRSF19 | (15) |
| rs1572072 | 13q12.12 | C | 1.16 (1.10–1.25) | 5.50E−08 | TNFRSF19 | (15) |
aOR and P-values were calculated based on combined samples. Ng et al. (13) consisted of 447 NPC patients and 764 healthy controls. Tse et al. (14) consisted of 912 NPC patient and 1925 healthy controls. Bei et al. (15) consisted of 5090 NPC patients and 4957 healthy controls. Our current study consisted of 703 NPC patients and 734 healthy controls.